Double-blind controlled trial of a micronized preparation of flumedroxone (Demigran) in prophylaxis of migraine.
A double-blind cross-over trial of a micronized preparation of flumedroxone, an oral progestogen derivative, and a placebo was undertaken to determine whether this drug had prophylactic value in migraine. No benefit was found in males, or in females with no history of menstrual exacerbation of migraine. In women whose migraine was worse around the time of menstruation flumedroxone resulted in statistically fewer headaches of less severity.With the dose used in this trial (micronized flumedroxone 10 mg. t.d.s.) side-effects were frequent, the commonest being polymenorrhagia, which occurred in half the women of reproductive age.
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008598:Menstruation; D008599:Menstruation Disturbances / Q000139:chemically induced; D008784:Methysergide / Q000009:adverse effects; D008881:Migraine Disorders / Q000517:prevention & control*; D010919:Placebos; D011278:Pregnanes / Q000627:therapeutic use*; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced; D014149:Tranquilizing Agents / Q000627:therapeutic use
D010919:Placebos; D011278:Pregnanes; D011372:Progestins; D014149:Tranquilizing Agents; D008784:Methysergide